Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Millions of Americans are born predisposed to high levels of a cholesterol called lipoprotein(a). Doctors are finally figuring out how to treat it.

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

Based on their dependence on IL-23, the theory that early use of high-dose IL-23 inhibitors might “induce long-term remissions or even cure” was recently tested in a prospective phase 2 trial ...

Physicians typically treat this chronic disorder with relatively high doses of the antibiotic doxycycline, often for prolonged periods of time. However, the drug can trigger nausea, vomiting, and ...

Starting your baby on solid foods is a milestone that’s both exciting and a little nerve-racking, but getting the right high chair can set you and your child up for success. Registered dietitian ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Pipeline Expansion: - Investments in early-stage pipeline include over 15 molecules in development. - Alvotech leads in developing EYLEA high dose and Entyvio biosimilars. - Symphony biosimilar ...